BMC Psychiatry
March 27, 2026
Samantha Carley, Robert B. Laprairie, Stephen Adams et al.
Abstract Background Psychotic disorders substantially impact individuals psychologically, occupationally, and socially. Although modifiable risk factors such as insecure attachment styles, history of psychological trauma, and substance use disorders (of which cannabis is the most frequent) are known to increase risk, it remains unclear how they may interact with each other to create pathways of...
ACS Chemical Neuroscience
February 18, 2026
Tallan Black, Rhiannon E Boseley, Amanda Quirk et al.
Perspectives surrounding Cannabis use have transformed over the past decade. This shift in perspective has been noted in pregnant populations in Canada and the US, where various investigations report that the use of Cannabis in pregnancy is increasingly commonplace. There is some evidence indicating that Δ9-tetrahydrocannabinol (THC), the main intoxicating phytocannabinoid found within Cannabis...
Current Topics in Medicinal Chemistry
July 6, 2023
Udoka C. Ezeaka, Hye Ji J. Kim, Robert B. Laprairie
1 citation
Abstract: Lysergic acid Diethylamide (LSD), psilocybin, and psilocin are being intensively evaluated as potential therapeutics to treat depression, anxiety, substance use disorder, and a host of other psychiatric illnesses. Pre-clinical investigation of these compounds in rodent models forms a key component of their drug development process. In this review, we will summarize the evidence...
Psychopharmacology
April 2021
Dan L McElroy, Andrew J Roebuck, Gavin A Scott et al.
Antipsychotics help alleviate the positive symptoms associated with schizophrenia; however, their debilitating side effects have spurred the search for better treatment options. Novel compounds can be screened for antipsychotic potential in neuronal cell cultures and following acute N-methyl-D-aspartate (NMDA) receptor blockade with non-competitive antagonists such as MK-801 in rodent...